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Edited by Veli-Pekka LehtoAbstract Activation of ErbB receptor tyrosine kinases triggers
multiple signaling pathways that regulate cellular proliferation
and survival. We here demonstrate that ErbB2 is activated via
the epidermal growth factor receptor (EGFR) upon exposure
of cultured human keratinocytes to 2-methyl-1,4-naphthoquinone
(menadione). Both ErbB2 and EGFR are shown to be regulated
by protein tyrosine phosphatases that are inhibited by menadi-
one, giving rise to the hypothesis that phosphatase inhibition
by menadione may result in a net activation of EGFR and an en-
hanced ErbB2 phosphorylation. Isolated PTP-1B, a protein
tyrosine phosphatase known to be associated with ErbB recep-
tors, is demonstrated to be inhibited by menadione.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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ErbB2 is a member of the ErbB family of receptor tyrosine
kinases (RTK) that also comprises the epidermal growth factor
receptor (EGFR = ErbB1), ErbB3 and ErbB4. An overexpres-
sion of ErbB2 is associated with the development of human
cancers, such as breast or ovarian cancer [1,2]. Activation of
ErbB2 requires heterodimerisation with other ErbB family
members as no high-aﬃnity ligand has been described for
ErbB2 [3]. Interaction with a ligand-bound dimerisation part-
ner results in tyrosine phosphorylation of the cytosolic do-
mains due to ErbB tyrosine kinase activity, yielding
phosphotyrosine residues that serve as docking sites for signal-
ing proteins [3]. ErbB2 is expressed in human skin [4], and it
tends to be overexpressed in basal cell carcinoma (BCC) and
downregulated in squamous cell carcinoma (SCC) relative to
normal epidermis [5].
In addition to ligand-induced activation, the ligand-indepen-
dent activation of receptor tyrosine kinases, including EGFR
and ErbB2, has been described for skin cells exposed to ultra-
violet (UV) radiation and was hypothesised to be due to the
inactivation of regulating tyrosine phosphatases by UV-de-
rived reactive oxygen species [6,7]. A similar mechanism for
the activation of EGFR-dependent signaling in rat liver epithe-
lial cells was proposed for the vitamin K analog, 2-methyl-1,4-*Corresponding author. Fax: +49 211 8113029.
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doi:10.1016/j.febslet.2006.02.048naphthoquinone (menadione), which was demonstrated to in-
hibit a yet unidentiﬁed protein tyrosine phosphatase (PTPase)
regulating the EGFR [8,9].
The present study investigates activation of ErbB receptors
in human keratinocytes exposed to menadione, focusing on
the interaction between ErbB2 and EGFR as well as the role
of PTPases. Menadione may serve as a model for environmen-
tal naphthoquinone derivatives, such as those found in plant
extract-based preparations for topical application to skin,
including plumbagin and juglone (from walnut extracts) as
well as lawsone (from henna leaves).
We demonstrate that exposure of human keratinocytes to
menadione leads to phosphorylation and activation of ErbB2,
independent of whether keratinocytes are immortalized and
tumorigenic or not. ErbB2 phosphorylation is via EGFR,
and both EGFR and ErbB2 phosphorylation are regulated
by menadione-sensitive PTPase(s) independent from each
other.2. Materials and methods
2.1. Cell culture
Normal human epidermal keratinocytes (NHEK), HaCaT and SCL-
1 cells were a kind gift of Dr. Peter Brenneisen, Du¨sseldorf, and were
held in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Sigma–Aldrich,
Deisenhofen, Germany) supplemented with (ﬁnal concentrations) 9%
(v/v) fetal calf serum (FCS; BioWest, Frickenhausen, Germany),
2 mM Glutamax (Gibco/Invitrogen, Karlsruhe, Germany), and peni-
cillin/streptomycin (100 U/ml and 0.1 mg/ml, respectively; PAA,
Co¨lbe, Germany) at 37 C in a humidiﬁed atmosphere with 5% (v/v)
CO2.
Cells grown to 90–100% conﬂuence in 28 cm2-dishes were exposed to
menadione (Sigma–Aldrich) diluted in serum-free medium for the
times indicated. DMSO was taken as vehicle control in the respective
appropriate concentration. EGFR kinase inhibitors (AG1478, com-
pound 56, all from Calbiochem, San Diego, CA, USA) were diluted
from stock solutions in DMSO. Accordingly, identical volumes of
DMSO were used as solvent controls where appropriate.2.2. Western blotting and immunoprecipitation
Keratinocytes were grown to 90–100% conﬂuence and serum-
starved over night before treatment with menadione. After treatment,
cells were lysed in RIPA buﬀer [20 mM Tris–Cl, pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1% (w/v) Triton X-100, 1 mM
Na3VO4, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate,
1 lg/ml leupeptin, 1 mM phenylmethylsulfonyl ﬂuoride], followed by
protein determination with a detergent-compatible protein assay
(Bio-Rad, Munich, Germany). Appropriate volumes of 2· SDS–
PAGE sample buﬀer [125 mM Tris–HCl, 4% (w/v) SDS, 20% (w/v)
glycerol, 100 mM DTT, and 0.2% (w/v) bromophenol blue, pH 6.8]
were added to protein extracts (usually 20 lg of protein per sample),
followed by heat denaturation of samples at 95 C for 5 min andblished by Elsevier B.V. All rights reserved.
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electrophoresis and Western blotting. For detection of phosphorylated
and total ErbB2, rabbit polyclonal anti-phospho-ErbB2 antibodies
detecting phosphorylation at Tyr-1139 or Tyr-1248 (both from Bio-
Source; Camarillo, CA, USA) and anti-total-ErbB2 (Upstate Biotech-
nology, Lake Placid, NY, USA, or Cell Signaling Technology, Beverly,
MA, USA) antibodies were used. Similarly, polyclonal anti-phospho-
EGFR (Tyr1068) (BioSource International) and anti-total-EGFR
(Upstate Biotechnology) antibodies were used at the dilutions recom-
mended by the suppliers. Furthermore, rabbit polyclonal anti-phos-
pho-ERK-1/2 and anti-total ERK-1/2 antibodies (both Cell Signaling
Technology) were employed. Horseradish peroxidase-coupled second-
ary antibodies were from Dianova (Hamburg, Germany) or Pierce
(Rockford, IL, USA), chemiluminescence detection reagents from
Pierce. For immunoprecipitation of EGFR, cells grown to near conﬂu-
ence in 64 cm2 dishes were lysed in 500 ll IP buﬀer (30 mM Tris, pH
7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10 mM NaF,
5 mM Na3VO4, 10 lg/ml aprotinin, 10 lg/ml leupeptin, 1 mM phenyl-
methylsulfonyl ﬂuoride), collected with a cell scraper and centrifuged
(10 min, 20000 · g, 4 C). Supernatants were transferred to fresh reac-
tion cups and analysed for protein content with a detergent-compatible
protein reagent (Bio-Rad). 700 lg of protein was then incubated with
4 lg of rabbit polyclonal anti-EGFR antibody (Upstate Biotechnol-
ogy) and 50 ll of a 50%-slurry of protein A-agarose (washed in IP buf-
fer; Upstate Biotechnology) for 14–20 h at 4 C under end over end
rotation. After a brief centrifugation to pellet the agarose beads, they
were washed twice with IP buﬀer and once with Tris–EDTA (25 mM
Tris, pH 6.8, 1 mM EDTA), followed by addition of 50 ll of 4·
SDS–PAGE sample buﬀer and an incubation at 95 C for 5 min. After
centrifugation, 20 ll of the respective supernatant was analysed by
SDS–PAGE and Western blotting.
2.3. Assay of ErbB2 and EGF receptor dephosphorylation
Dephosphorylation of ErbB2 as well as EGF receptor was analyzed
as described before [9,10]. Brieﬂy, HaCaT cells were grown to 80–100%
conﬂuency and serum-starved overnight. ErbB2 and EGF receptor
tyrosine phosphorylation was stimulated by incubation in the presence
of human recombinant EGF (100 ng/ml, R& D Systems, Minneapolis,
MN, USA) for 5 min. The cells were washed with PBS and exposed to
menadione (100 lM) or DMSO (solvent control) in serum-free
DMEM for the indicated times. Following treatment, cells were
washed with PBS brieﬂy and fresh serum-free medium containing the
EGFR tyrosine kinase inhibitor AG1478 (Calbiochem/Merck, Darms-
tadt, Germany; 10 lM) was added to prevent any further EGFR-
dependent phosphorylation. After 30 s, medium was quickly removed
and cells were lysed in 2· SDS–PAGE sample buﬀer, followed by
SDS–PAGE on a gel of 10% (w/v) acrylamide and Western blotting
with detection of phosphorylated ErbB2 and EGFR.
2.4. Phosphatase assay
Tyrosine phosphatase activity of the recombinant C-terminal re-
gion of human PTP-1B (Biomol, Hamburg, Germany) was measured
using p-nitrophenyl phosphate (pNPP, Sigma–Aldrich) as substrate.
PTP-1B (0.67 lM in 50 mM HEPES, pH 6.8) was preincubated with
either DMSO, menadione, 2,3-dimethoxy-1,4-naphthoquinone
(DMNQ, Sigma), or 2,3-bis-[2-hydroxyethylsulfanyl]-1,4-naphthoqui-
none (NSC95397, Sigma) at the given concentrations for 10 min at
room temperature in a volume of 50 ll and then added to 750 ll
of pNPP/HEPES (2 mM pNPP in 50 mM HEPES buﬀer, pH 6.8)
preequilibrated to 37 C. The subsequent increase in absorbance at
405 nm (associated with the formation of p-nitrophenolate) was mon-
itored, and the formation of p-nitrophenol/min calculated using an
absorption coeﬃcient of 18000 M1 cm1 after correction for p-nitro-
phenol ionisation.3. Results and discussion
3.1. Activation of ErbB2 by menadione
Exposure of human keratinocytes to menadione (100 lM)
resulted in strong tyrosine phosphorylation of ErbB2, as
demonstrated employing antibodies speciﬁcally recognizingphosphorylated Tyr-1139 (Fig. 1A) or phosphorylated Tyr-
1248 (see below, e.g. Fig. 1C). Similar to ErbB2, tyrosine
phosphorylation of EGFR was also elicited in cells exposed
to menadione, which is in line with previous reports on
EGFR activation by menadione in rat liver epithelial cells
[8]. Furthermore, signaling cascades downstream of ErbB2
and EGFR, such as those resulting in activation of extracel-
lular signal-regulated kinase (ERK)-1 and ERK-2, were acti-
vated (Fig. 1B). ErbB2 and EGFR phosphorylation signals
induced by exposure to menadione were comparable in inten-
sity to those caused by exposure of cells to EGF. Activation
of ErbB2 was elicited at concentrations of menadione start-
ing at 10 lM (data not shown) and was detectable after
10 min of exposure (Fig. 1C). When menadione was used at
50 lM rather than 100 lM to yield a slightly protracted cel-
lular response to exposure, it became evident that tyrosine
phosphorylation of ErbB2 continuously increased over at
least 2 h (Fig. 1C), pointing to either the gradual and slow
intracellular accumulation of menadione or to the slow accu-
mulation of an active intermediate generated by metabolism
of menadione.
ErbB2 and EGFR activation was similarly strong in primary
normal human epidermal keratinocytes (NHEK), in immortal-
ized but non-tumorigenic human keratinocytes (HaCaT) as
well as in immortalized and tumorigenic human keratinocytes
(squamous cell carcinoma, SCL-1; Fig. 1A).
3.2. Menadione activates ErbB2 via EGFR
Activation of ErbB2 requires heterodimerization with other
ErbB family members, including EGFR, which is a known
dimerisation partner. In fact, EGF activates ErbB2 in NHEK,
HaCaT and SCL-1 cells (Figs. 1A, 2A), which is blocked by
inhibitors of the EGFR tyrosine kinase activity, AG1478 and
‘‘compound 56’’ (Fig. 2A) at concentrations preventing
activation of EGFR (Fig. 2B). A signiﬁcant unspeciﬁc inhibi-
tion of ErbB2 by these inhibitors is unlikely as the employed
concentrations (10 lM of both AG1478 or compound 56) were
above IC50 values for inhibition of EGFR in vitro (AG1478:
3 nM, cpd 56:6 pM) to ensure a most eﬃcient blockade of
EGFR, and at the same time well below IC50 values for
inhibition of ErbB2 (AG1478: >100 lM) [11,12]. Furthermore,
inhibitors of ErbB2 tyrosine kinase activity, AG825 (ICErbB250 :
0.35 lM; ICEGFR50 : 19 lM) and AG879 (IC
ErbB2
50 : 1 lM;
ICEGFR50 : >500 lM) [11], neither blocked menadione-induced
nor EGF-induced ErbB2 tyrosine phosphorylation if added
to cells in concentrations of 10 lM (data not shown), implying
again that a kinase other than ErbB2 itself is responsible for
ErbB2 phosphorylation. In line with these data pointing to
an interaction of ErbB2 with EGFR, phospho-ErbB2 was
coimmunoprecipitated with phospho-EGFR from lysates of
EGF-stimulated cells (Fig. 2C, left panel). Surprisingly, ErbB2
was coprecipitated with EGFR even in unstimulated cells
(Fig. 2C, right panel, lane 3), implying that preformed
ErbB2/EGFR heterodimers exist that are not extensively tyro-
sine-phosphorylated. It was previously demonstrated that
EGFR homodimerisation not necessarily requires ligand bind-
ing [13], so the same might also apply for heterodimerization.
Interestingly, EGFR/ErbB2 heterodimers, although present,
do not appear to be the major form of EGFR occurring in hu-
man keratinocytes as EGFR phosphorylation is also not
blocked by the above-mentioned ErbB2 tyrosine kinase inhib-
itors (data not shown).
Fig. 1. Activation of ErbB2 and EGFR as well as downstream signaling in human keratinocytes exposed to menadione. Normal human epidermal
keratinocytes (NHEK), HaCaT human keratinocytes and human squamous cell carcinoma cells (SCL-1) were serum-starved overnight, followed by
exposure to menadione (MQ, 100 lM; DMSO was used as solvent control in these experiments) or EGF (100 ng/ml) in serum-free cell culture
medium for 15 min. Analysis of ErbB2 and EGFR phosphorylation (A) as well as of ERK-1 and ERK-2 (B) phosphorylation was done by Western
blotting, employing antibodies speciﬁcally recognizing the respective phosphorylated protein forms. Gel loading was controlled by analysis of total
levels of ErbB2, EGFR or ERK-1/2. (C) Serum-starved HaCaT cells were exposed to 50 lM menadione for the times indicated, lysed and analyzed
for ErbB2 phosphorylation by Western blotting. DMSO served as solvent control (–). Data are representative of three independent experiments
yielding similar results.
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was partly reversed by postincubation with N-acetyl cysteine
(NAc, Fig. 3), indicating that the oxidation of an essential cys-
teine residue to the level of a disulﬁde or sulfenic acid (sulfe-
nate) is involved in menadione-induced ErbB2/EGFR
activation. This oxidative component in ErbB activation by
menadione in HaCaT cells may result from redox cycling of
the quinone with concomitant generation of reactive oxygen
species (ROS). Indeed, the generation of ROS as well as the
depletion and oxidation of glutathione in rat hepatocytes ex-
posed to menadione were described already in the early
1980s [14–16]. In line with this, exposure of HaCaT cells to
menadione resulted in an enhanced oxidation of glutathione
to glutathione disulﬁde that was detectable already after 15
min of exposure to menadione (data not shown). The steady
increase in ErbB2 phosphorylation during longer exposure of
the cells to menadione (Fig. 1C) which was postulated above
to be due to the continuous formation and accumulation over
time of an active agent in the cells would be in accordance with
such generation of ROS during menadione redox cycling.
3.3. Tyrosine phosphatase inhibition by 1,4-naphthoquinones
Menadione is capable of inhibiting PTPases in cell-free sys-
tems [17] as well as in cell culture [8,18]. In order to test for a
modulation by menadione of PTPases that regulate ErbB2tyrosine phosphorylation, HaCaT cells were stimulated with
EGF to induce strong tyrosine phosphorylation of ErbB2
(Fig. 4A, lane 2 vs. lane 1). Addition of the EGFR tyrosine
kinase inhibitor AG1478 to block further EGFR-dependent
phosphorylation caused a rapid decline in ErbB2 tyrosine
phosphorylation (lane 4 vs. 2), pointing to the presence of
PTPases that dephosphorylate ErbB2. With menadione, how-
ever, ErbB2 remained phosphorylated, even in the presence of
AG1478 (lane 6 vs. 4), indicating that PTPases are prevented
from dephosphorylating the receptor. As demonstrated in
Fig. 4B, dephosphorylation of phospho-EGFR was also im-
paired by menadione, which is in line with previous data on
the inactivation of PTPases regulating EGFR phosphoryla-
tion by menadione in rat liver epithelial cells [8]. A time-
course analysis of phosphatase activity in cells exposed to
menadione (Fig. 4C) revealed that inhibition by menadione
of PTPase(s) targeting ErbB2 was detectable after 10, 30
and 60 min of incubation (lane 9 vs. 8). The inhibition elicited
by an exposure to menadione (10 min) was not relieved by
washing oﬀ the quinone and incubating the cells for another
60 min prior to addition of AG1478 and cell lysis (Fig. 4C,
bottom). Interestingly, after 30 min of exposure, menadione
was capable not only of activating ErbB2 without EGF but
to also keep it activated in the presence of AG1478 (lane 11
vs. 10).
Fig. 2. Role of EGFR in menadione-induced ErbB2 activation. HaCaT and SCL-1 cells were serum-starved overnight and incubated with DMSO
(solvent control) or the EGFR inhibitors AG1478 (10 lM) or compound 56 (c56, 10 lM) for 30 min prior to exposure of cells to menadione (MQ,
100 lM; DMSO was used as solvent control) or EGF (100 ng/ml) in serum-free cell culture medium for 15 min in the continued presence of the
inhibitors. Analysis of ErbB2 (A) or EGFR activation (B) was done by Western blotting employing appropriate antibodies speciﬁcally recognizing
the respective receptor phosphorylated at Tyr-1248 (ErbB2) or Tyr-1068 (EGFR). (C) Immunoprecipitation of EGFR in serum-starved HaCaT cells
treated with EGF (100 ng/ml; 15 min) where indicated and analysis of EGFR phosphorylation as well as of levels of co-precipitated total as well as
phosphorylated ErbB2. Data are representative of at least three independent experiments with similar results.
Fig. 3. Attenuation of menadione-induced ErbB2 activation by N-
acetyl cysteine. HaCaT cells were serum-starved overnight, exposed to
menadione (MQ, 100 lM) or DMSO (solvent control) for 15 min,
followed by a postincubation with serum-free medium with or without
N-acetyl cysteine (NAc; 3 mM) for 30 min prior to lysis and Western
blot analysis of ErbB2 and EGFR phosphorylation.
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menadione in rat liver epithelial cells is predominantly by ary-
lation [8]. In order to test the hypothesis that PTPase inactiva-
tion by menadione and other 1,4-naphthoquinones is mainly
by arylation, the inactivation of an isolated PTPase known
to associate with and to regulate phosphorylation of EGFR
and other receptor tyrosine kinases [19,20], the fragment con-
taining the catalytic domain of recombinant human PTP-1B
(residues 1–322) was incubated with menadione and two other
1,4-naphthoquinone derivatives, 2,3-dimethoxy-1,4-naphtho-
quinone (DMNQ) and NSC95397. The latter was analysed
for reasons of comparison as it was described as a most eﬃ-
cient inhibitor of cdc25 as well as other PTPases [21] and to
modulate EGFR tyrosine phosphorylation [22]. All three com-
pounds inhibited PTP-1B (Fig. 5), with NSC95397 being the
most eﬀective. IC50 values under the given conditions
(0.67 lM of PTP-1B were incubated with quinones at various
concentrations for 10 min) were 0.3, 16.5 and 56.2 lM for
Fig. 4. Inhibition of tyrosine phosphatase regulating ErbB2 by menadione. Serum-starved HaCaT cells were stimulated with EGF (100 ng/ml) for
5 min. Cells were washed with PBS and treated with 100 lMmenadione (MQ) for 15 min where indicated. Buﬀer was removed, and fresh serum-free
medium containing the EGFR tyrosine kinase inhibitor AG1478 (10 lM) was added to prevent any further EGFR-dependent phosphorylation.
After 30 s, medium was removed quickly, and cells were lysed, followed by Western blotting with detection of ErbB2 phosphorylated at Tyr-1248 or
Tyr-1139 (A) as well as of EGF receptor phosphorylated at Tyr-1068 (B). The levels of total ErbB2 and EGFR served as loading controls,
respectively. Lane 5: cells were treated with 0.1% DMSO, serving as solvent control for menadione. (C) HaCaT cells were treated as in (A), but
exposure to menadione was for 10, 30 or 60 min. Alternatively, a 10 min exposure to MQ was followed by 60 min incubation in menadione-free
medium prior to addition of AG1478. In lanes 2 and 7, lanes 3, 4 and 6 as well as lanes 8 and 10, although with identical labeling, cells were treated
with diﬀerent concentrations of DMSO for diﬀerent times, which served as vehicle control for AG1478 and/or MQ.
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non-arylating quinone, inhibiting PTP-1B signiﬁcantly less eﬃ-
ciently than menadione. Nevertheless, PTP-1B being inhibited
by DMNQ implies that arylation is not a strict requirement for
PTPase inhibition by 1,4-naphthoquinones. Rather, 1,4-naph-
thoquinones appear to be capable of inactivating PTPases by
noncovalent binding to the enzyme. Like DMNQ,
NSC95397 is a non-arylating naphthoquinone; its potency as
an inhibitor of cdc25 PTPases was proposed to be due to the
strong noncovalent binding in a position close to the active site
of the enzyme, with the two quinone oxygens forming hydro-
gen bonds with two guanidinium moieties of nearby arginine
residues [21]. In line with this, the 1,4-naphthoquinone scaﬀold
was found as a structure common to several cdc25 inhibitory
compounds [21]. It may be speculated that a similar mode of
inhibition occurs with naphthoquinones and PTP-1B.4. Conclusions
It is demonstrated here that ErbB2 is activated in human
keratinocytes exposed to menadione, a 1,4-naphthoquinone
derivative; this activation is via EGFR which interacts with
ErbB2. Menadione inhibits PTPases in cell-free systems and
in cultured cells, suggesting that ErbB activation by menadione
occurs indirectly by inhibition of PTPases negatively regulat-
ing both EGFR and ErbB2. These ﬁndings imply that other
1,4-naphthoquinones that may get in contact with human skin
could cause the same ligand-independent activation of ErbB
receptors that is found with menadione. Because of the prom-
inent role of ErbB receptors in the regulation of proliferation
and skin carcinogenesis this may raise concerns with regard
to a possible skin cancer promoting eﬀect of topically applied
1,4-naphthoquinone derivatives, occurring, for example, in
Fig. 5. Inhibition of PTP-1B by naphthoquinones. Recombinant
fragment containing the catalytic domain of human PTP-1B was
incubated in the presence of menadione (MQ), 2,3-dimethoxy-1,4-
naphthoquinone (DMNQ), or 2,3-bis-[2-hydroxyethylsulfanyl]-1,4-
naphthoquinone (NSC) prior to phosphatase activity determination.
Data are means of at least 3 independent measurements ± S.E.M.
(MQ) or means of two independent measurements (DMNQ, NSC). A
relative PTPase activity of 1.0 corresponds to a speciﬁc activity of
14.6 ± 5.0 lmol/min per mg protein (means ± S.D., n = 19) with
p-nitrophenyl phosphate as a substrate.
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are introduced in the present study; as ErbB2 activation by
menadione is via EGFR, the inhibition of EGFR will block
activity of EGFR as well as activation of ErbB2 (Fig. 2); sev-
eral ErbB inhibitors exist and are being developed for use in
humans [2]. Secondly, EGFR and ErbB2 activation by mena-
dione may be attenuated with N-acetyl cysteine (Fig. 3), sug-
gesting that antioxidative strategies could be successful in
blunting 1,4-naphthoquinone-induced ErbB activation in hu-
man skin.
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